A cutting-edge technology utilizing genetic-code expansion, non-canonical amino acid incorporation, has been also developed by Prof. Shigeyuki Yokoyama and his team at RIKEN, which enables site-specific modification of the target protein. At LiberoThera, we utilize the technology for drug discovery purposes.
